Carcinoma Transitional Cell Clinical Trial
Official title:
A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.
The mTOR (mammalian Target of Rapamycin) protein is the center of the mTOR pathway that plays
an important role in cell growth, proliferation, survival and angiogenesis through sensing
and integrating energetic signals from cellular environment. The mTOR protein is composed of
two complex, mTOR complex 1 (mTOR C1) and mTOR complex 2 (mTOR C2).
In regards of mTOR pathway dysregulations observed in TCC development, there is a rational to
test BEZ23 in advanced TCC. BEZ235 is a pan-class I PI3K inhibitor that, in addition, binds
to the catalytic site of mTOR, inhibiting mTOR C1 and mTOR C2.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05014139 -
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1 |